Turmeric Combined with Thalidomide Effectively Kills Cancer Cells
News Aug 21, 2013
Thalidomide was first introduced in the 1950s as an anti-nausea medication to help control morning sickness, but was later taken off the shelves in 1962 because it was found to cause birth defects. In the late 1990’s the drug was re-introduced as a stand-alone or combination treatment for multiple myeloma. Turmeric, an ancient spice grown in India and other tropical regions of Asia, has a long history of use in herbal remedies and has recently been studied as a means to prevent and treat cancer, arthritis and Alzheimer’s disease. According to the American Cancer Society, laboratory studies have shown that curcumin, an active ingredient in turmeric, interferes with several important molecular pathways and inhibits the formation of cancer-causing enzymes in rodents.
“Although thalidomide disturbs the microenvironment of tumor cells in bone marrow, it disintegrates in the body. Curcumin, also active against cancers, is limited by its poor water solubility. But the combination of thalidomide and curcumin in the hybrid molecules enhances both the cytotoxicity and solubility,” says the study’s lead researcher Shijun Zhang, assistant professor in the Department of Medicinal Chemistry at the Virginia Commonwealth University School of Pharmacy.
Compared to mixing multiple drugs, creating hybrid molecules can provide certain advantages. “Enhanced potency, reduced risk of developing drug resistance, improved pharmacokinetic properties, reduced cost and improved patient compliance are just a few of those advantages,” says another of the study’s researchers Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, program co-leader of Developmental Therapeutics and Cancer Cell Signaling research member at VCU Massey Cancer Center.
The hybrid molecules of turmeric and thalidomide created more than 15 compounds, each with a different effect. Scientists found that two of these compounds exhibited superior cell toxicity compared to curcumin alone or the combination of curcumin and thalidomide. Furthermore, the compounds were found to induce significant multiple myeloma cell death.
“Overall, the combination of the spice and the drug was significantly more potent than either individually, suggesting that this hybrid strategy in drug design could lead to novel compounds with improved biological activities,” added Grant. “The results also strongly encourage further optimization of compounds 5 and 7 to develop more potent agents as treatment options for multiple myeloma.”
Zhang and Grant collaborated on this study with Kai Liu from the Department of Medicinal Chemistry at the VCU School of Pharmacy; Jeremy Chojnacki, from the VCU Department of Medicinal Chemistry; Datong Zhang, from the School of Chemistry and Pharmaceutical Engineering at Shandong Polytechnic University in Jinan, Shandong; and Yuhong Du and Haian Fu, from the Department of Pharmacology and Emory Chemical Biology Discovery Center at Emory University in Atlanta, Georgia.
The laboratory, preclinical study was published by the journal Organic & Biomolecular Chemistry.
The full manuscript of this study is available below.